KALA BIO, Inc. operates as a clinical-stage biopharmaceutical company. The Company designs and develops proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts, and the female reproductive systems. KALA BIO markets its products worldwide.

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Current Report (Form 8-K | Period ending 2024-12-29)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

KALA BIO (KALA US)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Current Report (Form 8-K | Period ending 2024-12-29)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-09-23)

424B5 | Prospectus

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)